Asymptomatic Subacute Thyroiditis Following Pfizer mRNA Third Dose Confirmed to Resolve Spontaneously Within 6 Months
Background
Following the COVID-19 pandemic, as messenger RNA (mRNA) platform vaccines have been administered to billions worldwide, rare adverse events associated with immune responses have been steadily reported in academia. Among these, subacute thyroiditis (SAT) is an inflammatory disease that typically occurs following a viral infection, characterized by anterior neck pain and tenderness, fever, and transient thyroid dysfunction. Over 160 cases of SAT appearing after COVID-19 infection or vaccination have been documented in global medical literature, with the majority establishing a temporal relationship with the first or second doses.
However, clinical information has been lacking regarding potential thyroiditis patterns that are incidentally identified without subjective symptoms in patients with complex underlying diseases after a third dose. Typical SAT causes pain around the neck, prompting patients to seek immediate medical attention, but if it develops in a painless (silent) form without pain or fever, it is easy to miss the lesion in routine clinical practice. Especially when atypical blood test results are identified in patients undergoing regular follow-up for severe chronic diseases, failure to accurately determine the pathophysiology carries a high risk of subjecting patients to unnecessary drug prescriptions or excessive detailed examinations.
Key Findings
The research team performed a detailed analysis of an atypical SAT case identified in a 47-year-old male patient with no history of thyroid disease following his third dose of the Pfizer mRNA vaccine. The patient was under close observation for Clear Cell Renal Cell Carcinoma (ccRCC) and advanced Chronic Kidney Disease (CKD). Medical staff incidentally detected abnormal thyroid levels while conducting routine blood tests on the patient following his third dose.
The most distinctive feature was evident in the clinical course. The patient did not report any typical inflammatory signs, such as anterior neck pain, dysphagia, or high fever commonly observed in subacute thyroiditis (SAT). Because he maintained a continuous asymptomatic state with no subjective symptoms, the medical team adopted a cautious serological follow-up approach instead of aggressive medication. Even without the application of separate antithyroid drugs or corticosteroids, the deranged thyroid function indicators spontaneously returned to the normal range approximately 6 months after vaccination.
This case demonstrates that the third dose, in addition to initial doses, can act as a trigger for thyroid inflammation caused by immune responses. It holds academic value in confirming that even patients with serious underlying conditions may experience vaccine-induced SAT asymptomatically, following a self-limiting clinical course that stabilizes spontaneously within approximately 6 months without specific drug treatment.
Implications and Outlook
This case suggests that the spectrum of endocrine adverse reactions following mRNA vaccination may be broader than previously known categories. Painless subacute thyroiditis is extremely difficult to differentiate from painless lymphocytic thyroiditis or adverse drug reactions due to underlying conditions. If clinicians fail to recognize the temporal connection with vaccination history, it is highly likely to lead to excessive medical interventions, such as radioactive iodine uptake scans or indiscriminate antithyroid drug prescriptions, which can impose additional physical burdens on cancer patients with impaired kidney function.
As the development of new drugs using mRNA platform technology accelerates, the mechanisms by which immune amplification interacts with other endocrine organs must be clearly elucidated. Research is essential to reveal the pathways where molecular mimicry between vaccine antigens and thyroid follicular cell antigens, or systemic inflammatory mediators stimulated by Lipid Nanoparticle (LNP) adjuvants, combine with individual genetic predispositions. Because it is difficult to establish molecular causality due to the nature of a single case report, systematic follow-up studies—such as establishing large-scale multicenter registries to accurately determine incidence and identify high-risk groups—are required.
Over 160 cases of subacute thyroiditis (SAT) following COVID-19 vaccination or infection have been reported in the literature. Roughly one-half were attributed to either the first or second dose of the COVID-19 vaccine. We report a rare case of SAT in a 47-year-old male patient with a history of clear cell renal cell carcinoma and advanced chronic kidney disease, among other comorbidities, excluding thyroid disease. After he received the third dose of the Pfizer mRNA vaccine, a deranged thyroid profile was accidentally discovered. His SAT remained asymptomatic and normalized in about six months without treatment. SAT post-COVID vaccination is a self-limiting and rare condition that should be considered in the differential diagnosis of silent thyroiditis.
It provides clinical guidance to prioritize asymptomatic subacute thyroiditis in the differential diagnosis when patients with complex underlying conditions, such as cancer or chronic kidney disease, present with unexplained thyroid hormone abnormalities following vaccination. Even without typical pain, there is a high possibility of hormone leakage due to temporary follicular damage; therefore, an approach of monitoring progress through periodic blood tests over 3 to 6 months is recommended rather than hasty drug prescription. By establishing such a conservative observation strategy, unnecessary antithyroid drug administration or invasive biopsies can be prevented, simultaneously improving patient safety and reducing the waste of medical resources.